Search
Alglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalIt is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients. … Aglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes.
Products: Myozyme Powder for Solution for Injection, (Alglucosidase alfa) 50mg Powder for Solution for InfusionPegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigational[L44667] Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. … [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]
Products: ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML, Oncaspar 750 U/ml powder for solution for injection/infusionRisankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716]
Products: SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML, SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.83MLErenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalErenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marke...
Products: AIMOVIG (140 MG/ML SOLUTION FOR INJECTION), AIMOVIG (70 MG/ML SOLUTION FOR INJECTION)Tedizolid
go.drugbank.com/drugs/DB14569ApprovedInvestigationalThis product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: SIVEXTRO LYOPHILIZED POWDER FOR SOLUTION FOR INFUSION 200MG PER VIALBortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigationalBortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome ...
Products: Retrox 3.5mg Powder for Solution for Injection, BORTESUN POWDER FOR SOLUTION FOR INJECTION 3.5 mgOxaliplatin
go.drugbank.com/drugs/DB00526ApprovedInvestigationalOngoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. … [A797] Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal
Products: hovid Oxaliplatin 50mg Powder for Concentrate for Solution for Infusion, hovid Oxaliplatin 100mg Powder for Concentrate for Solution for InfusionTirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigationalagonist for this indication. … Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor
Products: Mounjaro 5 mg solution for injection in vial, Mounjaro 10 mg solution for injection in vialNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.
Products: OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML, Opdivo 10mg/ml, Concentrate for solution for infusionIbandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigational[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Categories: Drugs for Treatment of Bone DiseasesProducts: BONVIVA 3MG/3ML FER, IBANDRONSAEURE AL 3 MG FER